FORMULATION AND BIO-AVAILABILITY PARAMETERS OF PHARMACEUTICAL SUSPENSION

Authors

  • Pakpi Doye Regional Institute of Pharmaceutical Science and Technology, Abhoynagar, Agartala 799005, Tripura, India
  • Tanya Mena Regional Institute of Pharmaceutical Science and Technology, Abhoynagar, Agartala 799005, Tripura, India
  • Nilimanka Das Regional Institute of Pharmaceutical Science and Technology, Abhoynagar, Agartala 799005, Tripura, India

DOI:

https://doi.org/10.22159/ijcpr.2017.v9i3.18892

Keywords:

Formulation, Flocculation, Structured vehicles, Bio-availability factors

Abstract

The suspension is a biphasic liquid or semi-solid dosage form where the finely divided insoluble solid drug particles are homogeneously dispersed in a liquid or semi-solid medium. The solid drug particles act here as the dispersed phase and the liquid or the semi-solid as the dispersion medium. Suspensions contribute to pharmaceutical dosage form development by supplying drugs that are insoluble in all acceptable medium and often distasteful. Suspension translates such drugs into more bio-available form when compared to capsules, tablets, coated tablets, enteric coated tablets and sustained release products. The dosage form is palatable to the patient and many are doing well when applied to the skin or mucous membrane. This particular dosage form is also applied for injecting drugs into the systemic circulation. Therefore, pharmaceutical suspension finds its application through three different routes of administration namely oral, externally applied suspension and injectable one. The success of any dosage form largely depends on formulation parameters and the factors that influence the bioavailability which ultimately dictate the therapeutic success of the formulated dosage form. Hence, it is obvious to discuss the formulation parameters and the factors influencing bioavailability of suspension for the therapeutic success of it.

Downloads

Download data is not yet available.

References

Ancha MJ, Senthil kumar KL, Jackson DD. Formulation and evaluation of pediatric azithromycin suspension. Int J Pharma Bio Sci 2010;1:1-2.

Sushma G, Mahesh Kumar K, Ajay B, Ruchi T. Advancements and patents in pharmaceutical suspension technologies. J Biol Sci Opinion 2013;1:372-80.

Patel RM. Parenteral suspension: an overview. Int J Curr Pharm Res 2010;2:4-13.

Chukka S, Puligilla S, Yamsani MR. New formulation and evaluation of domperidone suspension. World J Pharm Pharm Sci 2014;3:1867-84.

Martin A. Physical pharmacy. 4th ed. Lippincott Williams and Wilkins; 1994. p. 480-2.

Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics-a treatise. 1st ed. Vallabh Prakashan, Delhi; 1995. p. 25-47.

Blandizzi C, Viscomi GC, Scarpignato C. Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug Des Dev Ther 2015;9:1-11.

Genovese DB. Shear rheology of hard-sphere, dispersed, and aggregated suspensions, and ï¬ller-matrix composites. Adv Colloid Interface Sci 2012;171-172:1-16.

Published

05-05-2017

How to Cite

Doye, P., T. Mena, and N. Das. “FORMULATION AND BIO-AVAILABILITY PARAMETERS OF PHARMACEUTICAL SUSPENSION”. International Journal of Current Pharmaceutical Research, vol. 9, no. 3, May 2017, pp. 8-14, doi:10.22159/ijcpr.2017.v9i3.18892.

Issue

Section

Review Article(s)